Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105

Kairos Pharma Ltd. (NYSE American: KAPA) has reported significant clinical progress in its cancer therapeutic development program, with positive interim results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer. The findings, detailed in a recent shareholder letter from CEO John Yu, M.D., demonstrate clinical benefit in 86% of treated patients, along with durable progression-free survival and no dose-limiting toxicities observed.

The clinical data, presented at the European Society for Medical Oncologists Meeting, indicates that ENV105 may extend the effectiveness of standard care while maintaining strong tolerability. This development is particularly significant given that ENV105 targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy often results in resistance and disease relapse, making ENV105's mechanism of action potentially transformative for cancer treatment.

Kairos Pharma continues to advance patient recruitment for the Phase 2 trial, with enrollment expected to reach 100 participants across leading U.S. cancer centers. The company's approach utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning ENV105 as a potential solution to one of oncology's most persistent challenges. Beyond prostate cancer, ENV105 is also being evaluated in a Phase 1 trial for lung cancer, addressing significant unmet medical needs across multiple cancer types.

The positive safety profile observed in the trial is noteworthy, as combination therapies often face toxicity challenges that limit their clinical utility. The absence of dose-limiting toxicities suggests ENV105 could be safely integrated with existing standard treatments, potentially creating new therapeutic options for patients who have developed resistance to conventional approaches. For investors and stakeholders seeking additional information, the company maintains updated resources at https://ibn.fm/YDPft.

This clinical progress represents an important step forward in addressing treatment resistance in advanced cancers, particularly in prostate cancer where limited options exist for patients who progress on standard therapies. The 86% clinical benefit rate, combined with the durable progression-free survival observed, suggests ENV105 could meaningfully extend treatment effectiveness for patients facing limited alternatives. As cancer treatment increasingly focuses on combination approaches and overcoming resistance mechanisms, Kairos Pharma's results position the company at the forefront of this critical therapeutic area.